|Application ||WB, FC, IP|
|Calculated MW||33048 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein A|
|Shelf Life||18 months from date of despatch.|
|Other Names||T-lymphocyte activation antigen CD80, Activation B7-1 antigen, BB1, CTLA-4 counter-receptor B7.1, B7, CD80, CD80, CD28LG, CD28LG1, LAB7|
|Target/Specificity||Mouse anti-Human CD80 antibody, clone MEM-233 recognizes human CD80, also known as B7-1, a ~60kDa type 1 trans-membrane protein expressed of macrophages, dendritic cells (Munroet al.1994) and activated B-cells (Ranheimet al.1993)CD80 is a member of the immunoglobulin superfamily having an extracellular domain bearing both a single Ig-v-like domain, a single Ig-c-like domain, a transmembrane sequence and a short cytoplasmic domain. Although the predicted molecular weight for human CD80 is ~33kDa, the presence of multiple (8) potential N-glycosylation sites (Chenet al.1998) results in a migration corresponding to ~60kDa.Human CD80 along with CD86 act as co-stimulatory molecules and are both ligands for CD28 and CTLA-4 (Azumaet al.1993) involved in T cell activation and proliferation (Vasuet al.2003). Although CD80 binds to the same receptors as CD86 it displays quite different characteristics in its avidity and binding kinetics (van der Merwe et al.1997).Site mutagenesis studies indicate residues in both the Ig-v-like and Ig-c-like domains of CD80 are crucial for the interaction with it’s receptors CTLA-4 and CD28 (Peachet al.1995).Mouse anti-human CD80 antibody, clone MEM-233 binds to residues within the Ig-v-like domain of human CD80 as shown by domain switching studies (Vasuet al.2003).Functional studies using Mouse anti-Human CD80, clone MEM-233 in combination with Mouse anti-Human CD86, clone Bu63 suggest that clone MEM-233 is able to block binding of human CD80 with it's cognate ligands CD28 and CTLA-4 (Morbachet al.2011).|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human CD80 Antibody, clone MEM-233 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Zhan, H. et al. (2003) The immunomodulatory role of human conjunctival epithelial cells.Invest. Opthalmol. Vis. Sci. 44: 3906-3910. 2. Angel, C.E. et al. (2006) Cutting edge: CD1a+ antigen-presenting cells in human dermis respond rapidly to CCR7 ligands.J. Immunol. 176: 5730-5734. 3. Daubenberger, C.A. et al. (2007) Flow cytometric analysis on cross-reactivity of human-specific CD monoclonal antibodies with splenocytes of Aotus nancymaae, a non-human primate model for biomedical research.Vet Immunol Immunopathol. 119: 14-20. 4. Hovden,. A.O. et al. (2011) Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses.BMC Immunol. 12: 2. 5. John, J. et al. (2010) Differential effects of Paclitaxel on dendritic cell function.BMC Immunol. 11: 14. 6. Newman, K.C. et al. (2006) Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria.PLoS Pathog. 2: e118. 7. Piconi, S. et al. (2010) Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4.J Immunol. 185: 7723-30. 8. Scheinecker, C. et al. (1998) Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells.J Immunol. 161: 3966-73. 9. Tan, P.H. et al. (2005) Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.Blood. 105: 3824-32. 10. Trojan, J. et al. (2010) Antisense anti IGF-I cellular therapy of malignant tumours: immune response in cancer patients.Biomed Pharmacother. 64: 576-8. 11. Huxley, P. et al. (2004) High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy.Chem Biol. 11: 1651-8. 12. Tan, P.H. et al. (2004) Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells.Atherosclerosis. 173: 171-83. 13. Silk, K.M. et al. (2012) Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141+XCR1+ dendritic cellsGene Ther. 19: 1035-40.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.